RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the "Company" or "Science 37"), the clinical research industry's leading MetasiteTM, today ...
RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™, today announced that its Chief Delivery ...
Clinical trials technology company Science 37 went public during the Covid-19 pandemic, a time when drug developers readily embraced technologies that enable patients to participate in drug studies ...
Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial ...
Science 37, a decentralized clinical trial operating system developer, has shared it's going public through a merger with special purpose acquisition company LifeSci Acquisition II Corp. Upon ...
Los Angeles-based research company Science 37 announced the completion of a clinical study for AOBiome Therapeutics conducted entirely through a smartphone app. The Phase 2b study ran on the back of ...
PLAYA VISTA, Calif.--(BUSINESS WIRE)--Science 37, a trailblazing company focused on “site-less” clinical trials, announced today the completion of a Phase 2b study for AOBiome, a clinical-stage life ...
LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Science 37 and Foundation Medicine today announced a collaboration to enable decentralized clinical research in oncology that will optimize recruitment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results